Strong Association between Two Polymorphisms on 15q25.1 and Lung Cancer Risk: A Meta-Analysis

Background: The association between polymorphisms on 15q25.1 and lung cancer has been widely evaluated; however, the studies have yielded contradictory results. We sought to investigate this inconsistency by performing a comprehensive meta-analysis on two polymorphisms (CHRNA3 gene: rs1051730 and AGPHD1 gene: rs8034191) on 15q25.1. Methods: Data were extracted from 15 and 14 studies on polymorphisms rs1051730 and rs8034191 involving 12301/14000 and 14075/12873 lung cancer cases/controls, respectively. The random-effects model was applied, addressing heterogeneity and publication bias. Results: The two polymorphisms followed Hardy-Weinberg equilibrium for all studies (P.0.05). For rs1051730-G/A, carriers of A allele had a 36 % increased risk for lung cancer (95 % confidence interval [CI]: 1.27–1.46; P,0.0005), without heterogeneity (P = 0.258) or publication bias (PEgger = 0.462). For rs8034191-T/C, the allelic contrast indicated that C allele conferred a 23 % increased risk for lung cancer (95 % CI: 1.08–1.4; P = 0.002), with significant heterogeneity (P,0.0005), without publication bias (PEgger = 0.682). Subgroup analyses suggested that the between-study heterogeneity was derived from ethnicity, study design, matched information, and lung cancer subtypes. For example, the association o